Sunday, March 1, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
No Result
View All Result
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
No Result
View All Result
No Result
View All Result

Vulnerable may need COVID-19 booster shots

Daily Remedy by Daily Remedy
June 5, 2021
in
0

People most vulnerable to Covid-19 could require a booster of the BioNTech/Pfizer vaccine later this year, according to scientists who said the shot elicited a lower antibody response against the Delta variant first identified in India.

A study by researchers at the Francis Crick Institute and UCLH Biomedical Research Centre found that levels of neutralising antibodies in recipients of two shots of the vaccine were, on average, more than five times lower against the Delta variant than the original strain that emerged in Wuhan, China.

Source: Financial Times

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions. Takeaways GLP-1 medications are not linked to pancreatic cancer. Peer-reviewed studies debunk misinformation about GLP-1s. Anecdotal evidence is not reliable for general conclusions. Observational studies have limitations in generalizability. Understanding study design is crucial for evaluating claims. Symptoms should be discussed in the context of clinical conditions. Not all side effects reported are relevant to every patient. Observational studies can provide valuable insights but are context-specific. Patients should critically assess the relevance of studies to their own experiences. Engagement in discussions about specific studies can enhance understanding Chapters 00:00 Debunking GLP-1 Medication Myths 02:56 Understanding Clinical Study Designs 05:54 The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

by Daily Remedy
March 1, 2026
0

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!

Twitter Updates

No Result
View All Result

© 2026 Daily Remedy